Gyre Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Gyre Therapeutics reports increased revenue in 2025 driven by new product launches and positive Phase 3 Hydronidone results, while announcing a merger with Cullgen Inc.
NASDAQ
Gyre Therapeutics reports a net income of $17.9 million for FY2024, driven by ETUARY sales and advancements in its F351 clinical program.
NASDAQ
Gyre Therapeutics' 10-K filing outlines the company's share structure, dividend history, and strategic focus on developing anti-fibrotic drugs.